{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:39:59Z","timestamp":1772120399517,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.bone.2009.01.009","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T04:56:22Z","timestamp":1232772982000},"page":"858-864","source":"Crossref","is-referenced-by-count":61,"title":["Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation"],"prefix":"10.1016","volume":"44","author":[{"given":"Regina","family":"Ebert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Zeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Krug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Meissner-Weigl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Seefried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Eulert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2009.01.009_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.oraloncology.2005.08.001","article-title":"Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases","volume":"42","author":"Bagan","year":"2006","journal-title":"Oral Oncol."},{"key":"10.1016\/j.bone.2009.01.009_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.01.009_bib3","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.01.009_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2009.01.009_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","article-title":"Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298","volume":"15","author":"Coxon","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.01.009_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","article-title":"Recent advances in understanding the mechanism of action of bisphosphonates","volume":"6","author":"Coxon","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bone.2009.01.009_bib7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bone.2009.01.009_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.bone.2009.01.009_bib9","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2009.01.009_bib10","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2009.01.009_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1359\/jbmr.2003.18.2.204","article-title":"Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro","volume":"18","author":"Frith","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.01.009_bib12","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1359\/jbmr.071207","article-title":"Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat","volume":"23","author":"Gasser","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl 4","key":"10.1016\/j.bone.2009.01.009_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.bone.2009.01.009_bib14","doi-asserted-by":"crossref","first-page":"28067","DOI":"10.1074\/jbc.M300373200","article-title":"The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow","volume":"278","author":"Gregory","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2009.01.009_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbrc.2007.01.014","article-title":"Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells","volume":"354","author":"Hashimoto","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2009.01.009_bib16","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bone.2009.01.009_bib17","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1634\/stemcells.2006-0753","article-title":"Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation","volume":"25","author":"Lee","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.bone.2009.01.009_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002512-200623040-00002","article-title":"Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence","volume":"23","author":"Liberman","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.bone.2009.01.009_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/(SICI)1097-4644(19990915)74:4<616::AID-JCB11>3.0.CO;2-Q","article-title":"Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro","volume":"74","author":"Malaval","year":"1999","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2009.01.009_bib20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jcp.1041580322","article-title":"Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures","volume":"158","author":"Malaval","year":"1994","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bone.2009.01.009_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates","volume":"147","author":"Monkkonen","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bone.2009.01.009_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.01.009_bib23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0736-0266(02)00018-9","article-title":"Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells","volume":"20","author":"Noth","year":"2002","journal-title":"J. Orthop. Res."},{"issue":"S1","key":"10.1016\/j.bone.2009.01.009_bib24","first-page":"P177","article-title":"Zoledronate potently inhibits the growth, function and survival of normal rat osteoblasts","volume":"80","author":"Orriss","year":"2007","journal-title":"Calcif. Tissue Int."},{"issue":"S1","key":"10.1016\/j.bone.2009.01.009_bib25","first-page":"M056","article-title":"Comparison of Gene Expression in Osteocytes versus Osteoblasts","volume":"23","author":"Paic","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.01.009_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1359\/jbmr.2004.19.1.147","article-title":"The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)","volume":"19","author":"Pan","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.01.009_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure","volume":"23","author":"Recker","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.01.009_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00024677-200605010-00003","article-title":"The treatment of severe postmenopausal osteoporosis: a review of current and emerging therapeutic options","volume":"5","author":"Reginster","year":"2006","journal-title":"Treat. Endocrinol."},{"key":"10.1016\/j.bone.2009.01.009_bib29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.01.009_bib30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease","volume":"353","author":"Reid","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.01.009_bib31","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1056\/NEJMc052601","article-title":"Paget's disease and bisphosphonates","volume":"353","author":"Rendina","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2009.01.009_bib32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2009.01.009_bib33","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bone.2009.01.009_bib34","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2009.01.009_bib35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bone.2006.03.011","article-title":"Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp90 in osteoblast-like cell lines","volume":"39","author":"Romanello","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.01.009_bib36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bone.2009.01.009_bib37","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2009.01.009_bib38","first-page":"801","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"35","author":"Sambrook","year":"2006","journal-title":"Aust. Fam. Physician"},{"issue":"2","key":"10.1016\/j.bone.2009.01.009_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jcb.21415","article-title":"Microarray analyses of transdifferentiated mesenchymal stem cells","volume":"103","author":"Schilling","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2009.01.009_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2007.03.004","article-title":"Plasticity in adipogenesis and osteogenesis of human mesenchymal stem cells","volume":"271","author":"Schilling","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bone.2009.01.009_bib41","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbrc.2005.09.198","article-title":"Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro","volume":"338","author":"Schindeler","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2009.01.009_bib42","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bone.2009.01.009_bib43","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.bone.2005.02.001","article-title":"Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts","volume":"36","author":"Vaes","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2009.01.009_bib44","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1359\/JBMR.050614","article-title":"Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells","volume":"20","author":"van der Horst","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2009.01.009_bib45","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1006\/bbrc.2002.6510","article-title":"Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts","volume":"291","author":"Viereck","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2009.01.009_bib46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.bone.2009.01.009_bib47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209000222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328209000222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T02:24:42Z","timestamp":1545445482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328209000222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S8756328209000222"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2009.01.009","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1159513.619889","asserted-by":"object"}]},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}